Dermatologist Highlights Medical Benefits of MelaFind Device in Aiding
Melanoma Diagnosis at Most Treatable Stage
“This is the wave of the future for dermatology.”
10th Annual Maui Derm Conference
MAUI, Hawaii & IRVINGTON, N.Y. -- January 30, 2014
MELA Sciences, Inc. (NASDAQ: MELA), developer of MelaFind^®, an FDA approved
optical diagnostic device that assists dermatologists in the diagnosis of
melanoma, hosted a MelaFind^® workshop during the 10^th Annual Maui Derm
Conference in Hawaii. The conference seeks to increase physicians’ knowledge
of developments in medical and cosmetic dermatology.
Dr. Monica Scheel, a Board Certified Dermatologist based in Hawaii, hosted the
MelaFind^® workshop which reviewed the clinical use and benefits of the device
as well as future technology development opportunities for the device and its
underlying optical imaging and data analysis technology. Dr. Scheel had also
presented clinical data at MELA Sciences’ Clinical Advisory meeting at the
Winter Clinical Dermatology Conference held a week earlier.
“Adding MelaFind to my practice has helped mobilize patients and drive disease
awareness; I’m thrilled with this new technology,” commented Dr. Scheel. “This
is the wave of the future for dermatology, a new way to visualize and analyze
atypical pigmented skin lesions below the skin surface. MelaFind has helped
increase the sensitivity of my biopsies, as well as helped me prioritize
lesions that can be monitored.”
MELA Sciences also displayed four clinical posters at the well-attended and
highly successful Maui Derm conference. The posters reviewed clinical data
from practice and clinical settings that highlighted how MelaFind has helped
dermatologists in the assessment of clinically ambiguous pigmented skin
lesions (moles) in a variety of patient types including young adults, an area
of growing concern, and those with atypical mole syndrome. The posters and
abstracts are available here.
About MELA Sciences, Inc. www.melasciences.com
MELA Sciences is a medical device company developing dermatology diagnostics
utilizing state-of-the-art optical imaging. The flagship product is
MelaFind^®, an FDA, PMA and CE Mark approved, non-invasive diagnostic tool to
aid dermatologists in melanoma evaluation and diagnosis. MelaFind^® uses a
variety of visible to near-infrared light waves to evaluate skin lesions
(moles) from the surface to 2.5 mm beneath the skin. It provides images and
data on the relative disorganization of a lesion's structure that provides
substantial additional perspective to aid melanoma diagnosis. MELA is also
exploring new potential uses for its core imaging technology and algorithms.
Twitter: MELASciencesIR or MelaFind
MELA Sciences, Inc.
Diana Garcia Redruello, 212-518-4226
Toni Trigiani, David Collins
Press spacebar to pause and continue. Press esc to stop.